In August, AbbVie launched its new pan-genomic hep C treatment Mavyret, costing $26,400 in the US for an eight week course, a deep undercutting of Epclusa’s list price of $74,760 for a 12 week ...

US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant. The suit ...

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (ENTA) (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and ...

Enanta Pharmaceuticals Inc Earnings Call Summary for Q2/2024 Q2 revenue at $17.1M, mainly from MAVYRET royalties; $300M cash on hand to fund operations through Q3 2027 Advancing RSV treatments ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with ...